Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04575428 · ClinicalTrials.gov registry record · Phase 2
Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04575428 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 5 participants.
The verdict
NCT04575428, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF) via volume redistribution from the splanchnic vascular bed to the central compartment. This is a sympathetically mediated reflex and can be interrupted through a splanchnic nerve block (SNB). We hypothesize that interruption of the efferent/afferent innervation of the splanchnic vasculature will decrease cardiac congestion in patients presenting with HF. Based on preliminary safety and efficacy data in acute and chronic heart failure patients with temporary (\<24 h) SNB. Now we will apply a prolonged SNB in chronic heart failure patients using a long acting agent. We will test the effects of SNB on long term exercise capacitance.
Interventions
- DRUG Splanchnic nerve block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2021-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04575428
The ClinicalTrials.gov registry entry for NCT04575428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Splanchnic nerve block is the first listed.
NCT04575428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04575428 about?
NCT04575428 is a clinical study titled "Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)". Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF) via volume redistribution from the splanchnic vascular bed to the central compartment. This is a sympathetically mediated reflex and can be interrupted through a splanchnic nerve block (SNB). We hypothesize th...
What is the current status of trial NCT04575428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-02-05. Estimated completion is 2021-06-16.
What interventions are being tested in trial NCT04575428?
The interventions under investigation include: Splanchnic nerve block (DRUG).
Who is sponsoring clinical trial NCT04575428?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.